Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration
Portfolio Pulse from
Myriad Genetics and Lumea have partnered to integrate Myriad's Prolaris and MyRisk tests into Lumea's BxLink platform, enhancing access to these diagnostic tools.
February 05, 2025 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Myriad Genetics has partnered with Lumea to integrate its Prolaris and MyRisk tests into Lumea's BxLink platform, potentially increasing the accessibility and usage of these tests.
The partnership with Lumea to integrate Myriad's tests into the BxLink platform could enhance the accessibility and adoption of these tests, potentially leading to increased revenue and market presence for Myriad Genetics.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90